You Belong and You Matter: An Exploration of Self-injurious Thoughts and Behaviors in LGTBQ+ Individuals

May 5, 2026 updated by: Konrad Bresin
Individuals with minoritized sexual and gender identities (i.e., LGBTQ+ individuals) are at a greater risk for self-injurious thoughts and behaviors than their cisgender, straight peers (Haas et al., 2010; Liu et al., 2017; Gorse, 2022). There is a dearth of empirically supported interventions for self-injurious thoughts and behaviors (Linehan, 2008; Riblet et al., 2017), and those that exist are not tailored to people in the LGBTQ+ community (Gorse, 2022; Haas et al., 2010). Therefore, the aim of this study is to test the effectiveness of a brief LGBTQ+ affirming text message intervention in reducing self-injurious thoughts and behaviors among LGBTQ+ individuals.

Study Overview

Status

Completed

Intervention / Treatment

Detailed Description

Scope of the work

LGBTQ+ individuals are at a greater risk for self-injurious thoughts and behaviors than their cisgender, straight peers. Despite this known risk, there are no culturally sensitive empirically supported treatments for self-injurious thoughts and behaviors for LBGTQ+ individuals. Therefore, the aim of this study is to test the effectiveness of a brief LGBTQ+ affirming text message intervention in reducing self-injurious thoughts and behaviors among LGBTQ+ individuals. Participants will be 100 LGBTQ+ adults who report self-injurious thoughts and/or behaviors in the last month. All participants will do 14 days of ecological momentary assessment (brief assessments on their mobile device 5 times a day) pre-randomization. After this period, half the participants will receive 2 brief affirming messages a day (morning and afternoon) for 14 days, and half of the participants will receive no messages for 14 days. The text messages will be designed to communicate belonging and importance for LGBTQ+ individuals in society (e.g., "There are over 9,000,000 LGBTQ+ people in the United States. You are not alone". Then all participants will complete another 14 days of ecological momentary assessment. During the assessment periods, participants will report on experiences of discrimination, belongingness, perceived burdensome, and self-injurious thoughts. We predict that participants in the mobile health condition will have a significant decrease in self-injurious thoughts and behaviors from pre- to post-intervention, whereas there will be no change in the control condition. We also predict that participants in the mobile health condition will lead to a significant decrease in thwarted belongingness and perceived burdensomeness. Finally, we predict that our intervention will help break the link between of experiences discrimination and self-injurious thoughts and behaviors by reducing feelings of thwarted belongingness and perceived burdensomeness in response to sexual and gender minority stress. If the effectiveness of our intervention is supported by the data, this intervention could be scaled up and be made available to the LGBTQ+ community broadly.

Study Type

Interventional

Enrollment (Actual)

55

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Kentucky
      • Louisville, Kentucky, United States, 40208
        • University of Louisville

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • be 18 years or older b) have an LGBTQ+ identity (e.g., a sexual orientation other than exclusively straight and/or a gender identity other than exclusively cisgender) c) report at least one self-injurious thought (e.g., suicidal or nonsuicidal self-injury ideation), or behavior (nonsuicidal self-injury, suicide attempt) in the last month

Exclusion Criteria:

  • Younger than 18, exclusivilty cisgender, heterosexual, no history of SITB in the last month

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Factorial Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Supportive Message Condition
Supportive messages
Participants received 28 supportive messages (2 per day) for 14 days
No Intervention: No Message Control
Control

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Self-injurious thoughts and behavior
Time Frame: last two hours
self reported
last two hours

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 15, 2024

Primary Completion (Actual)

October 30, 2024

Study Completion (Actual)

October 30, 2024

Study Registration Dates

First Submitted

October 16, 2025

First Submitted That Met QC Criteria

October 16, 2025

First Posted (Actual)

October 20, 2025

Study Record Updates

Last Update Posted (Actual)

May 11, 2026

Last Update Submitted That Met QC Criteria

May 5, 2026

Last Verified

May 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • ULouisville

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Control

Clinical Trials on Supportive Messages

Subscribe